• Explore /
  • Poster
  • / TST001 (a high affinity humanized anti-claudin18.2 monoclonal antibody) in combination with nivolumab plus capecitabine and oxaliplatin as first-line or with nivolumab as late-line treatment in locally advanced and metastatic gastric/gastroesophageal junction (G/GEJ) cancer: Design of cohorts from a phase I/IIa study (TST001-1002).

TST001 (a high affinity humanized anti-claudin18.2 monoclonal antibody) in combination with nivolumab plus capecitabine and oxaliplatin as first-line or with nivolumab as late-line treatment in locally advanced and metastatic gastric/gastroesophageal junction (G/GEJ) cancer: Design of cohorts from a phase I/IIa study (TST001-1002).

Abstract Video & Slides Poster

Authors

null

Weijian Guo

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China;

Weijian Guo , Caroline Germa , Chuan Qi , Chunhua Qian , Jenny Yao , Jianming Wang , Lijuan Zhang , Xueming Qian , Zhenzhong Xia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04495296

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS476)

DOI

10.1200/JCO.2023.41.4_suppl.TPS476

Abstract #

TPS476

Poster Bd #

N11

Abstract Disclosures

Similar Posters

First Author: Manish A. Shah

First Author: Zhi Peng

First Author: Lin Shen

First Author: Markus H. Moehler